Patent ID: 8980910
Filing Date: 2015-03-17
Classification: A61K,A61P

Abstract:
1. A method of treating glaucoma in a patient in need thereof, the method comprising administering to the patient an effective amount of a composition comprising an inhibitor of orexin activity, the inhibitor being an orexin antagonist selected from the group consisting of 1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-yl urea (SB334867), [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK4305), (2R)-2-[(1S)-6,7-dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydroisoquinolin-2(1H)-yl]-N-methyl-2-phenylacetamide (Almorexant), and combination thereof.